Insider Buying: Humacyte, Inc. (NASDAQ:HUMA) Director Acquires 50,000 Shares of Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Kathleen Sebelius bought 50,000 shares of the firm’s stock in a transaction dated Tuesday, April 8th. The stock was purchased at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the transaction, the director now directly owns 91,207 shares of the company’s stock, valued at $120,393.24. The trade was a 121.34 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Humacyte Stock Down 8.7 %

HUMA stock opened at $1.15 on Wednesday. Humacyte, Inc. has a 52 week low of $1.15 and a 52 week high of $9.97. The business has a 50-day simple moving average of $3.10 and a 200 day simple moving average of $4.28. The company has a market cap of $166.57 million, a PE ratio of -0.86 and a beta of 1.62.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. On average, analysts anticipate that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Humacyte by 85.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,825 shares of the company’s stock worth $1,024,000 after buying an additional 93,283 shares in the last quarter. Waverly Advisors LLC grew its position in Humacyte by 331.9% in the fourth quarter. Waverly Advisors LLC now owns 274,579 shares of the company’s stock valued at $1,387,000 after acquiring an additional 211,009 shares during the last quarter. Woodline Partners LP grew its position in Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock valued at $14,386,000 after acquiring an additional 2,000,268 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Humacyte during the fourth quarter worth about $132,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Humacyte by 30.4% in the fourth quarter. ProShare Advisors LLC now owns 30,852 shares of the company’s stock worth $156,000 after acquiring an additional 7,188 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on HUMA. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a report on Wednesday, March 26th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Humacyte has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.